The approval of over-the-counter HIV tests: Playing fair when making the rules

Journal of Business Ethics

Volumn 77, Issue 1, 2008, Pages 5-15

  Whellams, Melissa ^a  

^a SAINT MARY S UNIVERSITY   (Canada)

Author keywords

Biotechnology; Business ethics; Consumer autonomy; HIV testing; Home diagnostics; Marketing; Regulatory capture

Indexed keywords

EID: 36549024040     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-006-9300-5     Document Type: Article

References (31)

1. Bayer R., Stryker J., Smith M. D. (1995). Testing for HIV Infection at Home. The New England Journal of Medicine, 332(19):1295-1299
2. BPAC: 2005, 'Quick Minutes 85th Meeting - Nov 3-4, 2005', Retrieved February 21, 2006, from http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005- 4190M1_quick%20minutes.htm
3. Canadian HIV/AIDS Legal Network: 2001a, HIV Testing Info Sheet #11: Home Testing. Retrieved December 7, 2005 from http://www.aidslaw.ca/Maincontent/ issues/testing/e-info-ta11.pdf
4. Canadian HIV/AIDS Legal Network: 2001b, HIV Testing Info Sheet #18: Partner Notification. Retrieved February 21, 2006, from http://www.aidslaw.ca/ Maincontent/issues/testing/e-info-ta18.htm
5. Carpenter, D., M. Chernew, D.G. Smith and A.M. Fendrick: 2003, 'Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?', Health Affairs, W618-624
6. The Economist (2004) Business: From Bad to Awful. The Pharmaceuticals Industry. 272(8403):80
7. Eaton M. (2004). Ethics and the Business of Bioscience. Stanford, Stanford University Press
8. Ferrera, J. (1998, September/October). "Revolving Doors: Monsanto and the Regulators". The Ecologist 28, 5
9. Frerichs, R.: 1996, 'Home HIV Screening Debate', in: XI International Conference on AIDS, Vancouver, Canada, 8 July 1996. Retrieved March 5, 2006, from http://www.ph.ucla.edu/EPI/faculty/frerichs/debate.html
10. Gilding M. (2004) DNA paternity testing without the knowledge or consent of the mother: New technology, new choices, new debates. Family Matters 68:68-75
11. Gollust S. E., Hull S. C., Wilfond B. S. (2002) Limitations of direct-to-consumer advertising for clinical genetic testing. Journal of the American Medical Association, 288:1762-1767
12. Gollust S. E., Hull S. C., Wilfond B. S. (2003) Direct-to-consumer sales of genetic services on the Internet. Genetics in Medicine 5(4):332-337
13. Harris, G.: 2005, October 13, 'F.D.A. to Weigh At-Home Testing for AIDS Virus', New York Times
14. Lewis C. (2001) Home Diagnostic Tests: The Ultimate House Call? FDA Consumer Magazine 35:18-22
15. Leland, J.: 2005, November 5, 'U.S. Weighs Whether to Open an Era of Rapid H.I.V. Detection in the Home', New York Times
16. McCabe L. L., McCabe E. R. B. (2004) Direct-to-consumer genetic testing: Access and marketing. Genetics in Medicine 6(1):58-59
17. MedMira: 2005, 'Over-the-Counter HIV Testing: A Consumer Advocate Strategy', Presentation to the Blood Products Advisory Committee November 3, 2005. Retrieved February 23, 2006, from http://www.fda.gov/ohrms/dockets/ac/05/ slides/5-4190ws1_1.htm
18. Merson, M.: 1996, 'Home HIV Screening Debate', XI International Conference on AIDS, Vancouver, Canada, 8 July 1996. Retrieved March 5, 2006, from http://www.ph.ucla.edu/EPI/faculty/frerichs/debate.html
19. Metzler, N.: 2005, October 25, 'Advisory Committee to Review OTC HIV Test', PharmaExec
20. Miller H. I. (1999) The Real Curse of Frankenfoods. Nature Biotechnology, 17(2):113
21. Miller, J.: 2003, Beyond Biotechnology: FDA Regulation of Nanomedicine. The Columbia Science and Technology Law Review, Vol. IV. Retrieved February 15, 2006, from http://www.stlr.org/html/volume4/miller.pdf
22. Newell, P. and D. Glover: 2003, 'Business and Biotechnology: Regulation and the Politics of Influence', IDS Working Paper 192, Biotechnology Policy Series No.17, July 2003 (IDS, Brighton)
23. Newell, P. and D. Glover: 2004, 'Business and Biotechnology: Regulation of GM Crops and the Politics of Influence', in K. Jansen and S. Vellema (eds.), Agribusiness and Society: Corporate Responses to Environmentalism, Market Opportunities and Public Regulation (Zed Books, London), pp. 200-231
24. Olson, M. K.: 2003, (Jul-Dec) 'Explaining Reductions in FDA Drug Review Times: PDUFA Matters', Health Affairs, S1-S2
25. Schopper, D.: 1996, 'Home HIV Screening Debate', XI International Conference on AIDS, Vancouver, Canada, 8 July 1996. Retrieved March 5, 2006, from http://www.ph.ucla.edu/EPI/faculty/frerichs/debate.html
26. Skolnik et al. (2001) Deciding Where and How to Be Tested for HIV: What Matters Most? JAIDS Journal of Acquired Immune Deficiency Syndromes, 27(3):292-300
27. Spielberg et al. (2001). Moving from Apprehension to Action: HIV Counseling and Testing Preferences in three at-risk Populations. AIDS Education and Prevention, 13(6):524-540
28. San Francisco AIDS Foundation: 2005, 'Testimony before the Blood Products Safety Advisory Committee', November 3, 2005. Retrieved February 21, 2006, from http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4190ws1_1.htm
29. Who's Positive: 2005, 'Who's Positive to support Over-the-Counter (OTC) Rapid Home-Use HIV Test Kits to The Blood Products Advisory Committee', Press Information. Retrieved January 31, 2006, from http://www.whospositive.org/news/ news.php?newsid=20
30. William-Jones B. (1999). Re-Framing the Discussion: Commercial Genetic Testing in Canada. Health Law Journal 7:49-67
31. Williams-Jones B. (2003). Where There's a Web, There's a Way: Commercial Genetic Testing and the Internet. Community Genetics 6(1):46-57